Abeona Therapeutics Inc. (ABEO)
ABEO Stock Price Chart
Explore Abeona Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze ABEO price movements and trends.
ABEO Company Profile
Discover essential business fundamentals and corporate details for Abeona Therapeutics Inc. (ABEO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
19 Sept 1980
Employees
136.00
CEO
Vishwas Seshadri
Description
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
ABEO Financial Timeline
Browse a chronological timeline of Abeona Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.23, while revenue estimate is $12.24m.
Earnings released on 13 May 2026
EPS came in at -$0.30 surpassing the estimated -$0.33 by +9.09%, while revenue for the quarter reached $8.72m , beating expectations by +90.72%.
Earnings released on 17 Mar 2026
EPS came in at -$0.34 surpassing the estimated -$0.35 by +2.86%, while revenue for the quarter reached $5.40m , beating expectations by +22.05%.
Earnings released on 12 Nov 2025
EPS came in at -$0.10 surpassing the estimated -$0.27 by +62.96%.
Earnings released on 14 Aug 2025
EPS came in at $1.71 surpassing the estimated -$0.39 by +538.46%, while revenue for the quarter reached $400.00k , missing expectations by -93.87%.
Earnings released on 15 May 2025
EPS came in at -$0.24 surpassing the estimated -$0.35 by +31.43%.
Earnings released on 20 Mar 2025
EPS came in at -$0.24 surpassing the estimated -$0.43 by +44.19%.
Earnings released on 14 Nov 2024
EPS came in at -$0.31 surpassing the estimated -$0.38 by +18.42%.
Earnings released on 12 Aug 2024
EPS came in at -$0.75 falling short of the estimated -$0.33 by -127.27%.
Earnings released on 15 May 2024
EPS came in at -$0.53 falling short of the estimated -$0.47 by -12.77%.
Earnings released on 18 Mar 2024
EPS came in at -$0.64 falling short of the estimated -$0.51 by -25.49%, while revenue for the quarter reached $2.82m .
Earnings released on 13 Nov 2023
EPS came in at -$0.48 surpassing the estimated -$0.53 by +9.43%.
Earnings released on 8 Aug 2023
EPS came in at -$0.44 surpassing the estimated -$0.66 by +33.33%, while revenue for the quarter reached $3.50m .
Earnings released on 11 May 2023
EPS came in at -$0.54 surpassing the estimated -$0.58 by +6.90%.
Earnings released on 29 Mar 2023
EPS came in at $1.53 surpassing the estimated -$0.75 by +304.00%, while revenue for the quarter reached $68.00k , missing expectations by -93.20%.
Earnings released on 14 Nov 2022
EPS came in at -$1.48 surpassing the estimated -$1.78 by +16.85%.
Earnings released on 11 Aug 2022
EPS came in at -$2.08 falling short of the estimated -$1.25 by -66.40%, while revenue for the quarter reached $1.00m .
Stock split effective on 5 Jul 2022
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 May 2022
EPS came in at -$2.50 falling short of the estimated -$2.00 by -25.00%, while revenue for the quarter reached $346.00k , beating expectations by +36.36%.
Earnings released on 31 Mar 2022
EPS came in at -$3.50 falling short of the estimated -$3.25 by -7.69%, while revenue for the quarter reached $3.00m .
Earnings released on 15 Nov 2021
EPS came in at -$4.00 matching the estimated -$4.00.
Earnings released on 28 Jul 2021
EPS came in at -$4.00 matching the estimated -$4.00.
ABEO Stock Performance
Access detailed ABEO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
